Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the
efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants
with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose
chemotherapy and autologous stem cell transplantation.